Business
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Exosome Platform for COVID-19-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies--Preclinical Data Shows Positive Antibody
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"Exosome Platform for COVID-19-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies--Preclinical Data Shows Positive Antibody Response-\n CAP-1002 for COVID-19-Expanded Access Emergency Use Series Published in Peer Reviewed Journal--Randomized, Double-Blind, Placebo-Controlled, Phase II IND Submitted to FDA--Plan to Initiate Study in Third Quarter, Subject to FDA Approval- Duchenne Muscular Dystrophy Program-Reported Positive Top-Line 12-month Results from HOPE-2 Study--In Discussions with FDA on Next Steps in Pathway Forward- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today its financial results for the second quarter ending June 30, 2020 and provided a corporate update. “We had a very successful first half of 2020, marked by continued achievements in our expanding cell and exosome programs. We are now well underway in animal studies and have seen promising results showing the mRNA vaccine is capable of generating an antibody response to multiple antigens expressed by COVID-19. Two distinct vaccines are now in development, one using the exosomes as virus-like particles and the other using exosomes loaded with viral protein mRNAs. We are moving forward as quickly as possible with the goal of bringing a vaccine into the clinic.” “Additionally, we have submitted a new investigational new drug application (IND) to the FDA for a randomized, placebo-controlled, double-blind, Phase II clinical trial to treat up to 60 patients in severe or critical condition with COVID-19 with CAP-1002. Furthermore, we continue to discuss next steps in our DMD program with the FDA” said Linda Marbán, Ph.D., Capricor’s president and chief executive officer. Dr. Marbán continued, “We are enthusiastic and encouraged to be engaged in the development of the next generation of potential vaccines using our proprietary exosome platform. Exosomes are intercellular communicators and are uniquely suited and have the potential to change how we treat, immunomodulate, and mediate serious life-threatening illnesses, correct genetic disorders, engineer...